Medifast (NYSE:MED) Releases FY 2026 Earnings Guidance

Medifast (NYSE:MED) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of -2.750–1.55 for the period, compared to the consensus EPS estimate of -1.380. The company issued revenue guidance of $270.0 million-$300.0 million, compared to the consensus revenue estimate of $355.1 million. Medifast also updated its Q1 2026 guidance to -0.700–0.15 EPS.

Analyst Upgrades and Downgrades

Several research firms have commented on MED. Weiss Ratings restated a “sell (d)” rating on shares of Medifast in a report on Thursday, January 22nd. Wall Street Zen upgraded Medifast from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Medifast currently has a consensus rating of “Reduce” and an average target price of $16.50.

Medifast Trading Up 0.1%

Shares of NYSE:MED traded up $0.01 during trading on Tuesday, reaching $10.78. The stock had a trading volume of 176,137 shares, compared to its average volume of 223,627. The firm’s 50-day simple moving average is $11.36 and its 200 day simple moving average is $12.34. Medifast has a one year low of $10.10 and a one year high of $16.45. The company has a market capitalization of $118.48 million, a P/E ratio of 1,078.00 and a beta of 0.53.

Hedge Funds Weigh In On Medifast

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its position in Medifast by 103.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock worth $32,000 after buying an additional 1,187 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Medifast in the 3rd quarter worth about $37,000. Intesa Sanpaolo Wealth Management acquired a new position in Medifast in the 4th quarter valued at $47,000. State of Wyoming acquired a new position in Medifast during the fourth quarter worth about $59,000. Finally, Strs Ohio acquired a new stake in shares of Medifast in the first quarter valued at approximately $78,000. Hedge funds and other institutional investors own 95.51% of the company’s stock.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.